Calmtop RTU Inj. (Irinotecan)
Product Description
HK inno. N Coorporation
-
KR -
2020On CPHI since
Company types
Categories
Specifications
HK inno. N Coorporation
-
KR
-
2020On CPHI since
Company types
More Products from HK inno. N Coorporation (2)
-
Product Tegoprazan
Tegoprazan is a novel patented Potassium-Competitive Acid Blocker (P-CAB) which alleviates the limitations of the historical Proton Pump Inhibitors (PPIs) and of other competing P-CABs.
Tegoprazan's competitive advantages have been demonstrated via Phase 3 clinical studies conducted in Korea a... -
Product Atomet XR Tab. (Atorvastatin + Metformin)
Fixed Dose Combination drug, indicated for Type2 Diabetes with Hyperlipidemia with Clinical trials phase Ⅰ & Ⅲ
HK inno. N Coorporation resources (1)
-
News HK inno.N Corporation receives regulatory approval for first novel drug
Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance